Key result
ACS is linked to markedly higher pro-BNP and ischemia-modified albumin versus noncardiac chest pain.
Why the study?
Detecting myocardial ischemia remains challenging because conventional markers like cardiac troponin and CK-MB do not directly detect ischemia.
Are pro-BNP and Ischemia Modified Albumin (IMA) levels elevated early in patients with acute coronary syndrome compared to those with noncardiac chest pain?
Case-Control (n=120)
Are pro-BNP and Ischemia Modified Albumin (IMA) levels elevated early in patients with acute coronary syndrome compared to those with noncardiac chest pain?
Pro-BNP and Ischemia Modified Albumin (IMA) levels are significantly elevated early in acute coronary syndrome compared to noncardiac chest pain, suggesting potential utility as early diagnostic markers.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for pro-BNP and IMA as early ACS markers; prospective validation required before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2020 study conducted a case-control in Acute Coronary Syndrome (STEMI and NSTEMI) (n=120). pro-BNP and Ischemia Modified Albumin (IMA) measurement vs. Noncardiac chest pain (NCCP) controls was evaluated on pro-BNP and Ischemia Modified Albumin (IMA) levels at admission. Pro-BNP and Ischemia modified albumin levels were higher in acute coronary syndrome patients compared to noncardiac chest pain controls.
Synapse has enriched 10 related papers. Consider them for comparative context: